Subcategory & Sub-subcategory
Specifications
- Expression System: Mammalian cell line expression system with DMF filing, optimized for high titer and broad media adaptability
- Purity: High degree of analytical comparability to the reference product
- Regulatory Status: Approved in the European Union, Iceland, Liechtenstein and Norway (21 April 2021); DMF-filed cell line for global regulatory readiness
- Application: PD-1 inhibitor monoclonal antibody targeting neoplasms, urogenital and nervous-system diseases; representative indications include microsatellite-instability-high and mismatch-repair-deficient endometrial carcinoma
Leave your rating & comment